Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Macrogenics Inc (MGNX)
since 2014 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Macrogenics Inc.
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 1125345.
Total stock buying since 2014: $35,955,090.
Total stock sales since 2014: $17,696,557.
Total stock option exercises since 2014: $4,346,541.
Table 3. Detailed insider trading at Macrogenics Inc (MGNX) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2019-05-20 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Sale | 3,000 | 18.38 | 55,131 |
| 2019-05-20 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 3,000 | .94 | 2,820 |
| 2019-03-14 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 2,497 | .94 | 2,347 |
| 2019-02-06 | Peters Jeffrey Stuart (General Counsel) | Sale | 68 | 30.00 | 2,040 |
| 2019-02-06 | Spitznagel Thomas (Sr VP, BPD & Manufacturing) | Sale | 1,770 | 30.00 | 53,100 |
| 2019-02-06 | Spitznagel Thomas (Sr VP, BPD & Manufacturing) | Option Ex | 1,770 | 7.51 | 13,292 |
| 2019-02-06 | Fust Matthew K | Sale | 6,924 | 29.38 | 203,427 |
| 2019-02-06 | Fust Matthew K | Option Ex | 6,924 | 20.15 | 139,518 |
| 2019-01-28 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 6,000 | .94 | 5,640 |
| 2019-01-24 | Karrels James (SVP, CFO and Secretary) | Option Ex | 7,326 | .94 | 6,886 |
| 2019-01-08 | Karrels James (SVP, CFO and Secretary) | Option Ex | 5,314 | .94 | 4,995 |
| 2019-01-03 | Koenig Scott (President and CEO) | Option Ex | 39,897 | .94 | 37,503 |
| 2018-12-18 | Karrels James (SVP, CFO and Secretary) | Option Ex | 5,000 | .94 | 4,700 |
| 2018-12-12 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 5,000 | .94 | 4,700 |
| 2018-11-27 | Karrels James (SVP, CFO and Secretary) | Option Ex | 3,000 | .94 | 2,820 |
| 2018-11-13 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 4,000 | .94 | 3,760 |
| 2018-11-13 | Koenig Scott (President and CEO) | Option Ex | 40,000 | .94 | 37,600 |
| 2018-10-22 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 3,000 | .94 | 2,820 |
| 2018-03-12 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Sale | 1,000 | 31.08 | 31,080 |
| 2018-03-12 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 1,000 | .94 | 940 |
| 2018-03-05 | Karrels James (SVP, CFO and Secretary) | Sale | 5,000 | 31.00 | 155,000 |
| 2018-03-02 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Sale | 4,000 | 30.00 | 120,000 |
| 2018-03-02 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 4,000 | .94 | 3,760 |
| 2018-02-28 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Sale | 1,000 | 25.00 | 25,005 |
| 2018-02-28 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 1,000 | .94 | 940 |
| 2018-02-28 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 23,967 | 25.01 | 599,438 |
| 2018-02-28 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 23,967 | 1.13 | 27,082 |
| 2018-01-24 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Sale | 3,000 | 22.50 | 67,500 |
| 2018-01-24 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 3,000 | .94 | 2,820 |
| 2018-01-17 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 2,000 | .94 | 1,880 |
| 2018-01-17 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 2,524 | 20.00 | 50,480 |
| 2018-01-17 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 2,524 | 4.70 | 11,862 |
| 2018-01-16 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 2,476 | 20.00 | 49,520 |
| 2018-01-16 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 2,476 | 4.70 | 11,637 |
| 2018-01-16 | Karrels James (SVP, CFO and Secretary) | Option Ex | 6,516 | .94 | 6,125 |
| 2017-12-29 | Karrels James (SVP, CFO and Secretary) | Option Ex | 3,000 | .94 | 2,820 |
| 2017-11-21 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 5,000 | 20.00 | 100,000 |
| 2017-11-21 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2017-10-25 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 10,000 | 20.00 | 200,000 |
| 2017-10-25 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 10,000 | 4.70 | 47,000 |
| 2017-09-05 | Risser Eric Blasius (Sr VP & Chief Business Officer) | Option Ex | 2,000 | .94 | 1,880 |
| 2017-09-05 | Karrels James (SVP, CFO and Secretary) | Option Ex | 5,000 | .94 | 4,700 |
| 2017-07-26 | Bonvini Ezio (Sr VP, Research & CSO) | Option Ex | 53,264 | 1.23 | 65,248 |
| 2017-06-05 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 5,000 | 20.00 | 100,000 |
| 2017-06-05 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2017-04-19 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 15,000 | 20.00 | 300,000 |
| 2017-04-19 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 15,000 | 4.70 | 70,500 |
| 2017-01-25 | Karrels James (SVP, CFO and Secretary) | Option Ex | 5,000 | .94 | 4,700 |
| 2017-01-17 | Koenig Scott (President and CEO) | Option Ex | 79,898 | .94 | 75,104 |
| 2016-10-19 | Bonvini Ezio (Sr VP, Research & CSO) | Option Ex | 5,349 | .94 | 5,028 |
| 2016-10-03 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Sale | 10,000 | 29.34 | 293,400 |
| 2016-10-03 | Wigginton Jon Marc (Sr VP, Clinical Dev. & CMO) | Option Ex | 10,000 | 4.70 | 47,000 |
| 2016-10-03 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 6,231 | 29.28 | 182,443 |
| 2016-10-03 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 6,231 | .94 | 5,857 |
| 2016-08-01 | Wigginton Jon Marc (Sr VP Clinical Dev & CMO) | Sale | 20,000 | 30.78 | 615,600 |
| 2016-08-01 | Wigginton Jon Marc (Sr VP Clinical Dev & CMO) | Option Ex | 20,000 | 4.70 | 94,000 |
| 2016-07-01 | Wigginton Jon Marc (Sr VP Clinical Dev & CMO) | Sale | 5,000 | 27.22 | 136,100 |
| 2016-07-01 | Wigginton Jon Marc (Sr VP Clinical Dev & CMO) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2016-07-01 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 8,922 | 27.22 | 242,856 |
| 2016-07-01 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 8,922 | .94 | 8,386 |
| 2016-05-27 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 5,000 | 25.00 | 125,000 |
| 2016-05-27 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 5,000 | .94 | 4,700 |
| 2016-05-16 | Koenig Scott (President and CEO) | Option Ex | 34,619 | .94 | 32,541 |
| 2016-05-11 | Koenig Scott (President and CEO) | Option Ex | 79,898 | .94 | 75,104 |
| 2016-03-03 | Costa Paulo F | Buy | 10,000 | 17.20 | 172,000 |
| 2016-02-11 | Bonvini Ezio (Sr VP, Research & CSO) | Option Ex | 11,962 | .94 | 11,244 |
| 2016-02-08 | Risser Eric Blasius (SVP, Business Development) | Option Ex | 2,500 | .94 | 2,350 |
| 2016-01-29 | Karrels James (SVP, CFO and Secretary) | Option Ex | 10,000 | .94 | 9,400 |
| 2016-01-07 | Bonvini Ezio (Senior VP, Research) | Option Ex | 13,316 | .94 | 12,517 |
| 2016-01-07 | Stein Kathryn E (SVP, Product Dev. & Regulatory) | Option Ex | 52,350 | .89 | 46,800 |
| 2016-01-04 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 10,000 | 29.64 | 296,400 |
| 2016-01-04 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 10,000 | 4.70 | 47,000 |
| 2015-12-23 | Risser Eric Blasius (SVP, Business Development) | Option Ex | 1,500 | .94 | 1,410 |
| 2015-11-23 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 6,921 | 35.00 | 242,235 |
| 2015-11-23 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 1,185 | .94 | 1,113 |
| 2015-11-16 | Bonvini Ezio (Senior VP, Research) | Sale | 3,117 | 31.44 | 97,998 |
| 2015-10-15 | Bonvini Ezio (Senior VP, Research) | Sale | 6,233 | 25.21 | 157,133 |
| 2015-10-13 | Bonvini Ezio (Senior VP, Research) | Option Ex | 29,042 | 13.12 | 381,031 |
| 2015-10-07 | Karrels James (SVP, CFO and Secretary) | Option Ex | 6,000 | .94 | 5,640 |
| 2015-10-02 | Bonvini Ezio (Senior VP, Research) | Option Ex | 17,877 | .94 | 16,804 |
| 2015-10-01 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 5,000 | 21.11 | 105,550 |
| 2015-10-01 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2015-09-18 | Bonvini Ezio (Senior VP, Research) | Option Ex | 7,000 | .94 | 6,580 |
| 2015-09-16 | Bonvini Ezio (Senior VP, Research) | Option Ex | 4,000 | .94 | 3,760 |
| 2015-08-27 | Bonvini Ezio (Senior VP, Research) | Option Ex | 5,000 | .94 | 4,700 |
| 2015-08-26 | Bonvini Ezio (Senior VP, Research) | Option Ex | 5,000 | .94 | 4,700 |
| 2015-08-10 | Bonvini Ezio (Senior VP, Research) | Option Ex | 4,000 | .94 | 3,760 |
| 2015-08-03 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 10,000 | 37.15 | 371,500 |
| 2015-08-03 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 10,000 | 4.70 | 47,000 |
| 2015-07-10 | Bonvini Ezio (Senior VP, Research) | Sale | 2,400 | 38.09 | 91,416 |
| 2015-07-10 | Bonvini Ezio (Senior VP, Research) | Option Ex | 2,400 | .71 | 1,704 |
| 2015-07-01 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 5,000 | 37.15 | 185,750 |
| 2015-07-01 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2015-07-01 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 6,921 | 37.15 | 257,115 |
| 2015-07-01 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 8,815 | .94 | 8,286 |
| 2015-06-30 | Bonvini Ezio (Senior VP, Research) | Sale | 6,497 | 38.07 | 247,340 |
| 2015-06-30 | Bonvini Ezio (Senior VP, Research) | Option Ex | 6,497 | .71 | 4,612 |
| 2015-06-24 | Bonvini Ezio (Senior VP, Research) | Sale | 6,097 | 38.08 | 232,173 |
| 2015-06-23 | Bonvini Ezio (Senior VP, Research) | Sale | 13,054 | 38.14 | 497,879 |
| 2015-06-15 | Bonvini Ezio (Senior VP, Research) | Sale | 6,233 | 34.01 | 211,984 |
| 2015-06-15 | Bonvini Ezio (Senior VP, Research) | Option Ex | 6,233 | .71 | 4,425 |
| 2015-06-15 | Cilinski Lynn (VP, Controller and Treasurer) | Sale | 10,700 | 35.00 | 374,500 |
| 2015-06-15 | Cilinski Lynn (VP, Controller and Treasurer) | Option Ex | 5,000 | .94 | 4,700 |
| 2015-05-15 | Bonvini Ezio (Senior VP, Research) | Sale | 6,233 | 30.24 | 188,485 |
| 2015-05-15 | Bonvini Ezio (Senior VP, Research) | Option Ex | 6,233 | .71 | 4,425 |
| 2015-04-15 | Bonvini Ezio (Senior VP, Research) | Sale | 6,233 | 33.98 | 211,797 |
| 2015-04-15 | Bonvini Ezio (Senior VP, Research) | Option Ex | 6,233 | .71 | 4,425 |
| 2015-04-01 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 5,000 | 30.86 | 154,300 |
| 2015-02-02 | Wigginton Jon Marc (Sr VP, Clinical) | Sale | 5,000 | 31.04 | 155,200 |
| 2015-02-02 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 5,000 | 4.70 | 23,500 |
| 2014-04-01 | Wigginton Jon Marc (Sr VP, Clinical) | Option Ex | 5,000 | 4.70 | 23,500 |
Insider trading activities including stock purchases, stock sales, and option exercises
of MGNX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Macrogenics Inc (symbol MGNX,
CIK number 1125345) see
the Securities and Exchange Commission (SEC) website.